MolMed S.p.A. (MLM.MI) announces today receipt of the official notification from the European Patent Office of the decision to grant a patent covering the therapeutic use of its investigational anticancer drug NGR-hTNF at low doses. The grant will take effect on the 2nd of October 2013, when it will be published in the European Patent […]
MolMed TK: MolMed Board of Directors approves the first half-year 2013 financial report
TK: new data presented at ASCO 2013 show that the TK therapy enabled the execution of haploidentical donor transplants, with an overall survival similar to transplants from fully compatible donors NGR-hTNF: presented at ASCO 2013 final data from a randomised Phase II study indicating a 50% reduction in the risk of death in first-line treatment […]
MolMed ASCO Prolonged Survival Times Patients With Acute Leukaemia Treated With TK
Long-term data presented at ASCO confirm prolonged survival times of patients with acute leukaemia treated with TK cell therapy The use of TK has enabled the execution of haploidentical donor transplants, with an overall survival similar to transplants from fully compatible donors MolMed expects to file a request for Conditional Marketing Authorisation of TK to […]
MolMed ASCO 2013: New data presented on NGR-hTNF
New data presented at ASCO on NGR-hTNF: significantly increase in survival in squamous NSCLC and clinical benefit in sarcomas – Final results from a randomised Phase II study indicate a 50% relative reduction in the risk of death in first-line squamous lung cancer – Optimal treatment regimen with statistically significant improvement in progression […]
MolMed TK four studies accepted for presentation at ASCO 2013
MolMed S.p.A. (MLM.MI) today announced that four studies on its investigational therapeutics NGR-hTNF and TK have been accepted for presentation at the 49th ASCO Annual Meeting, that will take place in Chicago (IL, USA) from May 31st to June 4th, 2013. Abstracts are now available on the ASCO 2013 website (http://chicago2013.asco.org). This year yet again […]
MolMed NGR-hTNF: MolMed Board of Directors approves the interim financial report at 31 March 2013
The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 31 March 2013. The most important elements were: progress on dossier preparation to file a market authorisation application for TK through the Conditional Marketing Authorisation procedure with the European Medicines Agency; continuation of ongoing […]